In today’s life sciences landscape, reputation and capital are no longer separate concerns but are co-dependent drivers of enterprise value. Hannah Deresiewicz and Ethan Metelenis from Precision AQ’s Investor Relations and External Communications (IREC) team reveal why leading biotech and pharma organizations are embracing an integrated IREC model: a unified approach that aligns investor relations and external messaging to build trust, drive valuation, and accelerate growth.
In an era of investor skepticism, media scrutiny, and regulatory pressure, fragmented messaging is a liability. The IREC model transforms communications from a reactive function into a proactive capability that delivers clarity, speed, and resilience across every stakeholder touchpoint.
